Comparative Pharmacology
Head-to-head clinical analysis: CALOMIST versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALOMIST versus KETOTIFEN FUMARATE.
CALOMIST vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calomist (calcium gluconate) provides calcium ions to stabilize cardiac cell membranes, correct hypocalcemia, and antagonize hyperkalemia-induced cardiotoxicity.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
Mist inhalation: 1-2 actuations (100-200 mcg) delivered orally via nebulizer every 6 hours as needed for bronchospasm; maximum 12 actuations per day.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours; prolonged in renal impairment (up to 20 hours in anuria)
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Renal: 90% unchanged; biliary/fecal: 10%
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category C
Category A/B
Mast Cell Stabilizer
Antihistamine / Mast Cell Stabilizer